Reduced intensity conditioning and allogeneic stem cell transplantation after salvage therapy integrating alemtuzumab for patients with relapsed peripheral T-cell non-Hodgkin's lymphoma

被引：28

作者：

Wulf, GG ^{[1
]}

Hasenkamp, J ^{[1
]}

Jung, W ^{[1
]}

Chapuy, B ^{[1
]}

Truemper, L ^{[1
]}

Glass, B ^{[1
]}

机构：

[1] Univ Gottingen, Dept Hematol & Oncol, D-37099 Gottingen, Germany

来源：

BONE MARROW TRANSPLANTATION | 2005年 / 36卷 / 03期

关键词：

D O I：

10.1038/sj.bmt.1705036

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：271 / 273

页数：3

共 13 条

[1] Establishment of early donor engraftment after reduced-intensity allogeneic hematopoietic stem cell transplantation to potentiate the graft-versus-lymphoma effect against refractory lymphomas [J].

Bishop, MR ;

Hou, JWS ;

Wilson, WH ;

Steinberg, SM ;

Odom, J ;

Castro, K ;

Kasten-Sportes, C ;

Gea-Banacloche, J ;

Marchigiani, D ;

Gress, R ;

Fowler, DH .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (03) :162-169

[2] Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with Anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma [J].

Chanan-Khan, A ;

Islam, T ;

Alam, A ;

Miller, KC ;

Gibbs, J ;

Barcos, M ;

Czuczman, MS ;

Paplham, P ;

Hahn, T ;

McCarthy, P .

LEUKEMIA & LYMPHOMA, 2004, 45 (08) :1673-1675

[3] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[4]

Coiffier B, 1998, BLOOD, V92, P1927

[5] Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells [J].

Corradini, P ;

Dodero, A ;

Zallio, F ;

Caracciolo, D ;

Casini, M ;

Bregni, M ;

Narni, F ;

Patriarca, F ;

Boccadoro, M ;

Benedetti, F ;

Rambaldi, A ;

Gianni, AM ;

Tarella, C .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2172-2176

[6] High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H [J].

Dearden, CE ;

Matutes, E ;

Cazin, B ;

Tjonnfjord, GE ;

Parreira, A ;

Nomdedeu, B ;

Leoni, P ;

Clark, FJ ;

Radia, D ;

Rassam, SMB ;

Roques, T ;

Ketterer, N ;

Brito-Babapulle, V ;

Dyer, MJS ;

Catovsky, D .

BLOOD, 2001, 98 (06) :1721-1726

[7] A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas [J].

Enblad, G ;

Hagberg, H ;

Erlanson, M ;

Lundin, J ;

MacDonald, AP ;

Repp, R ;

Schetelig, J ;

Seipelt, G ;

Österborg, A .

BLOOD, 2004, 103 (08) :2920-2924

[8]

Gisselbrecht C, 1998, BLOOD, V92, P76

[9] Reduced-intensity conditioning prior to allogeneic transplantation of hematopoietic stem cells:: the need for T cells early after transplantation to induce a graft-versus-lymphoma effect [J].

Glass, B ;

Nickelsen, M ;

Dreger, P ;

Claviez, A ;

Hasenkamp, J ;

Wulf, G ;

Trümper, L ;

Schmitz, N .

BONE MARROW TRANSPLANTATION, 2004, 34 (05) :391-397

[10] Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma [J].

Moskowitz, CH ;

Bertino, JR ;

Glassman, JR ;

Hedrick, EE ;

Hunte, S ;

Coady-Lyons, N ;

Agus, DB ;

Goy, A ;

Jurcic, J ;

Noy, A ;

O'Brien, J ;

Portlock, CS ;

Straus, DS ;

Childs, B ;

Frank, R ;

Yahalom, J ;

Filippa, D ;

Louie, D ;

Nimer, SD ;

Zelenetz, AD .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) :3776-3785

← 1 2 →